Novo Nordisk sees 'painful' US price cuts for Wegovy as investment in the future
- - Novo Nordisk sees 'painful' US price cuts for Wegovy as investment in the future
ReutersFebruary 4, 2026 at 12:06 AM
0
Mike Doustdar, President and CEO of Novo Nordisk poses for a picture in Bagsvaerd, Denmark, August 7, 2025. Ritzau Scanpix/Mads Claus Rasmussen/via REUTERS
COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk CEO Mike Doustdar said on Wednesday that the price reductions for its obesity drug Wegovy in the U.S. are "painful" for the company's financial results but he hopes that they will be an investment in the future as many more people will be able to get access to the medicines as a result.
Doustdar was speaking with journalists after the company on Tuesday gave a far worse-than-expected outlook for 2026 and flagged a tough weight-loss market battle ahead as prices come under pressure.
(Reporting by Maggie Fick and Jacob Gronholt-Pedersen, editing by Stine Jacobsen)
Source: “AOL General News”
